-$0.51 EPS Expected for Tocagen Inc (NASDAQ:TOCA) This Quarter

Equities research analysts predict that Tocagen Inc (NASDAQ:TOCA) will announce earnings per share (EPS) of ($0.51) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Tocagen’s earnings, with estimates ranging from ($0.55) to ($0.46). Tocagen posted earnings of ($0.96) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 46.9%. The firm is expected to report its next earnings report on Wednesday, February 26th.

On average, analysts expect that Tocagen will report full year earnings of ($2.62) per share for the current year, with EPS estimates ranging from ($2.91) to ($1.83). For the next year, analysts anticipate that the company will report earnings of ($1.60) per share, with EPS estimates ranging from ($2.59) to ($0.24). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Tocagen.

Tocagen (NASDAQ:TOCA) last released its earnings results on Tuesday, November 12th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.10). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. Tocagen had a negative net margin of 201,488.91% and a negative return on equity of 182.15%.

Several analysts have weighed in on the company. Citigroup downgraded Tocagen from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $20.00 to $1.00 in a research report on Friday, September 13th. LADENBURG THALM/SH SH cut shares of Tocagen from a “buy” rating to a “neutral” rating in a report on Thursday, September 12th. Chardan Capital restated a “hold” rating on shares of Tocagen in a report on Monday, November 25th. Zacks Investment Research downgraded shares of Tocagen from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, B. Riley lowered shares of Tocagen from a “buy” rating to a “neutral” rating in a report on Thursday, September 12th. Ten investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $10.23.

TOCA remained flat at $$0.63 on Friday. The company had a trading volume of 122,222 shares, compared to its average volume of 408,913. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.46. The stock’s 50 day moving average price is $0.64 and its two-hundred day moving average price is $3.37. The company has a market capitalization of $15.18 million, a PE ratio of -0.26 and a beta of 3.88. Tocagen has a fifty-two week low of $0.53 and a fifty-two week high of $14.36.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Parametric Portfolio Associates LLC bought a new position in Tocagen during the 2nd quarter valued at approximately $75,000. A.R.T. Advisors LLC bought a new stake in shares of Tocagen in the 2nd quarter worth approximately $114,000. Dowling & Yahnke LLC grew its position in shares of Tocagen by 41.2% in the 2nd quarter. Dowling & Yahnke LLC now owns 17,122 shares of the company’s stock worth $114,000 after buying an additional 5,000 shares during the last quarter. IPG Investment Advisors LLC purchased a new position in shares of Tocagen during the second quarter valued at approximately $134,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Tocagen by 8.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 50,940 shares of the company’s stock valued at $341,000 after buying an additional 3,767 shares during the period. 27.62% of the stock is owned by institutional investors and hedge funds.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Featured Article: What causes a stock to be most active?

Get a free copy of the Zacks research report on Tocagen (TOCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.